MAM-2201 (analytically confirmed) intoxication after "synthacaine" consumption

Davide Lonati; Eleonora Buscaglia; Pietro Papa; Antonella Valli; Teresa Coccini; Andrea Giampreti; Valeria Margherita Petrolini; Sarah Vecchio; Giovanni Serpelloni; Carlo Alessandro Locatelli

doi:10.1016/j.annemergmed.2014.01.007

MAM-2201 (analytically confirmed) intoxication after "synthacaine" consumption

Davide Lonati, Eleonora Buscaglia, Pietro Papa, Antonella Valli, Teresa Coccini, Andrea Giampreti, Valeria Margherita Petrolini, Sarah Vecchio, Giovanni Serpelloni, Carlo Alessandro Locatelli

Research output: Contribution to journal › Article › peer-review

Abstract

Excitatory behavior, xerostomia, chest pain, severe dyspnea, tachycardia (150 beats/min), and mild hypertension (160/80 mm Hg) without ECG abnormalities were observed in a 20-year-old subject 6 hours after nasal insufflation (snorting) of a "legally" obtained white powdered substance sold as Synthacaine. A serum sample was found to contain MAM-2201 (11 ng/mL), a synthetic cannabinoid receptor agonist, and benzocaine. The patient's symptoms improved after administration of diazepam and intravenous fluids. Synthacaine was sold as legal cocaine, suggesting the user can expect an effect like that of cocaine. The pharmacologic receptor profile and chemical structure of MAM-2201 is similar to the synthetic cannabinoid receptor agonists AM-2201 and JWH-122 (2 potent synthetic cannabinoid receptor agonists with high affinity to cannabinoid receptors).

Original language	English
Pages (from-to)	629-632
Number of pages	4
Journal	Annals of Emergency Medicine
Volume	64
Issue number	6
DOIs	https://doi.org/10.1016/j.annemergmed.2014.01.007
Publication status	Published - Dec 1 2014

ASJC Scopus subject areas

Emergency Medicine
Medicine(all)

Access to Document

10.1016/j.annemergmed.2014.01.007

Cite this

@article{16f8829b3f3e49c1925ef8e031530853,

title = "MAM-2201 (analytically confirmed) intoxication after {"}synthacaine{"} consumption",

abstract = "Excitatory behavior, xerostomia, chest pain, severe dyspnea, tachycardia (150 beats/min), and mild hypertension (160/80 mm Hg) without ECG abnormalities were observed in a 20-year-old subject 6 hours after nasal insufflation (snorting) of a {"}legally{"} obtained white powdered substance sold as Synthacaine. A serum sample was found to contain MAM-2201 (11 ng/mL), a synthetic cannabinoid receptor agonist, and benzocaine. The patient's symptoms improved after administration of diazepam and intravenous fluids. Synthacaine was sold as legal cocaine, suggesting the user can expect an effect like that of cocaine. The pharmacologic receptor profile and chemical structure of MAM-2201 is similar to the synthetic cannabinoid receptor agonists AM-2201 and JWH-122 (2 potent synthetic cannabinoid receptor agonists with high affinity to cannabinoid receptors).",

author = "Davide Lonati and Eleonora Buscaglia and Pietro Papa and Antonella Valli and Teresa Coccini and Andrea Giampreti and Petrolini, {Valeria Margherita} and Sarah Vecchio and Giovanni Serpelloni and Locatelli, {Carlo Alessandro}",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/j.annemergmed.2014.01.007",

language = "English",

volume = "64",

pages = "629--632",

journal = "Annals of Emergency Medicine",

issn = "0196-0644",

publisher = "Mosby Inc.",

number = "6",

}

TY - JOUR

T1 - MAM-2201 (analytically confirmed) intoxication after "synthacaine" consumption

AU - Lonati, Davide

AU - Buscaglia, Eleonora

AU - Papa, Pietro

AU - Valli, Antonella

AU - Coccini, Teresa

AU - Giampreti, Andrea

AU - Petrolini, Valeria Margherita

AU - Vecchio, Sarah

AU - Serpelloni, Giovanni

AU - Locatelli, Carlo Alessandro

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Excitatory behavior, xerostomia, chest pain, severe dyspnea, tachycardia (150 beats/min), and mild hypertension (160/80 mm Hg) without ECG abnormalities were observed in a 20-year-old subject 6 hours after nasal insufflation (snorting) of a "legally" obtained white powdered substance sold as Synthacaine. A serum sample was found to contain MAM-2201 (11 ng/mL), a synthetic cannabinoid receptor agonist, and benzocaine. The patient's symptoms improved after administration of diazepam and intravenous fluids. Synthacaine was sold as legal cocaine, suggesting the user can expect an effect like that of cocaine. The pharmacologic receptor profile and chemical structure of MAM-2201 is similar to the synthetic cannabinoid receptor agonists AM-2201 and JWH-122 (2 potent synthetic cannabinoid receptor agonists with high affinity to cannabinoid receptors).

AB - Excitatory behavior, xerostomia, chest pain, severe dyspnea, tachycardia (150 beats/min), and mild hypertension (160/80 mm Hg) without ECG abnormalities were observed in a 20-year-old subject 6 hours after nasal insufflation (snorting) of a "legally" obtained white powdered substance sold as Synthacaine. A serum sample was found to contain MAM-2201 (11 ng/mL), a synthetic cannabinoid receptor agonist, and benzocaine. The patient's symptoms improved after administration of diazepam and intravenous fluids. Synthacaine was sold as legal cocaine, suggesting the user can expect an effect like that of cocaine. The pharmacologic receptor profile and chemical structure of MAM-2201 is similar to the synthetic cannabinoid receptor agonists AM-2201 and JWH-122 (2 potent synthetic cannabinoid receptor agonists with high affinity to cannabinoid receptors).

UR - http://www.scopus.com/inward/record.url?scp=84914112407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914112407&partnerID=8YFLogxK

U2 - 10.1016/j.annemergmed.2014.01.007

DO - 10.1016/j.annemergmed.2014.01.007

M3 - Article

C2 - 24530110

AN - SCOPUS:84914112407

VL - 64

SP - 629

EP - 632

JO - Annals of Emergency Medicine

JF - Annals of Emergency Medicine

SN - 0196-0644

IS - 6

ER -

MAM-2201 (analytically confirmed) intoxication after "synthacaine" consumption

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this